openPR Logo
Press release

Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer

05-20-2024 09:07 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Retinopathy pipeline constitutes 50+ key companies continuously working towards developing 55+ Diabetic Retinopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Diabetic Retinopathy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Retinopathy Market.

The Diabetic Retinopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diabetic Retinopathy Pipeline Report: https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Diabetic Retinopathy treatment therapies with a considerable amount of success over the years.
• Diabetic Retinopathy companies working in the treatment market are , and others, are developing therapies for the Diabetic Retinopathy treatment
• Emerging Diabetic Retinopathy therapies in the different phases of clinical trials are- , and others are expected to have a significant impact on the Diabetic Retinopathy market in the coming years.
• In May 2023, Oculic Holding AG unveiled favorable initial outcomes from Stage 1 of the Phase III DIAMOND trial concerning OCS-01 eye drops in diabetic macular edema (DME). The trial's Stage 1 successfully confirmed the intended dosing regimen's efficacy for OCS-01 in treating diabetic macular edema, achieving substantial statistical significance as per the company's statement.
• In April 2023, Palatin Technologies announced the publication of a manuscript titled "Stimulating the Melanocortin System in Uveitis and Diabetes Preserves the Structure and Anti-Inflammatory Activity of the Retina" in The International Journal of Molecular Sciences. The manuscript, authored by Tat Fong Ng and Andrew W. Taylor from the Department of Ophthalmology at Boston University Chobanian and Avedisian School of Medicine in Massachusetts, summarizes findings on PL8331's effects in experimental autoimmune uveoretinitis (EAU) and diabetic retinopathy (DR) in mouse models of retinal disease. The study received funding support from Palatin, the National Institute of Health (NIH), and the Massachusetts Lions Eye Research Foundation.
• In February 2023, Ocugen revealed the submission of an Investigational New Drug application (IND) to the US Food and Drug Administration (FDA) for the commencement of a Phase 1 clinical trial evaluating OCU200. This fusion protein, showcasing a unique mechanism of action (MOA), aims to address diabetic macular edema (DME). The accomplishment of this regulatory milestone fulfills Ocugen's commitment to file the OCU200 IND within the initial quarter of 2023.
• In January 2023, Ocuphire Pharma disclosed the top-line findings of its ZETA-1 Phase II trial, assessing oral APX3330 for diabetic retinopathy (DR) treatment. The trial demonstrated promising safety and tolerability of oral APX3330, hinting at its potential as a non-invasive option for safeguarding vision in both eyes among patients with DR.
• In May 2022, EyePoint Pharmaceuticals disclosed the licensing agreement of EYP-1901 to Betta Pharmaceuticals for development and commercialization in China, Hong Kong, Macau, and Taiwan. While retaining all rights for EYP-1901 globally, EyePoint broadens its exclusive rights concerning the local delivery of vorolanib. This expansion encompasses the treatment of various ophthalmic diseases, encompassing diabetic macular edema (DME).

Diabetic Retinopathy Overview
One eye-related consequence of diabetes is diabetic retinopathy. Damage to the blood vessels in the retina, the light-sensitive tissue in the back of the eye, is the root cause of it. Diabetic retinopathy may initially only produce minor vision impairment or no symptoms at all. But blindness may result from it. Any person with type 1 or type 2 diabetes has the potential to acquire the illness.

Get a Free Sample PDF Report to know more about Diabetic Retinopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Diabetic Retinopathy Drugs Under Different Phases of Clinical Development Include:
• PL8177: Palatin Technologies
• ABI-110: Avirmax Biopharma
• OTX-TKI: Ocular Therapeutix, Inc.
• MS-553: MingSight Pharmaceuticals, Inc
• OTT166: OcuTerra Therapeutics, Inc.
• RC28-E injection: RemeGen Co., Ltd.
• KSI-301: Kodiak Sciences Inc

Diabetic Retinopathy Route of Administration
Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Diabetic Retinopathy Molecule Type
Diabetic Retinopathy Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Diabetic Retinopathy Pipeline Therapeutics Assessment
• Diabetic Retinopathy Assessment by Product Type
• Diabetic Retinopathy By Stage and Product Type
• Diabetic Retinopathy Assessment by Route of Administration
• Diabetic Retinopathy By Stage and Route of Administration
• Diabetic Retinopathy Assessment by Molecule Type
• Diabetic Retinopathy by Stage and Molecule Type

DelveInsight's Diabetic Retinopathy Report covers around 55+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Diabetic Retinopathy product details are provided in the report. Download the Diabetic Retinopathy pipeline report to learn more about the emerging Diabetic Retinopathy therapies
https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Diabetic Retinopathy Therapeutics Market include:
Key companies developing therapies for Diabetic Retinopathy are - Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, Palatin Technologies, Valo Health, EyePoint Pharmaceuticals, Kubota Vision, MingSight Pharmaceuticals, Oxurion, Aerie Pharmaceuticals, AsclepiX Therapeutics, Ocugen, Ashvattha Therapeutics, Stealth BioTherapeutics, and others.

Diabetic Retinopathy Pipeline Analysis:
The Diabetic Retinopathy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Retinopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Retinopathy Treatment.
• Diabetic Retinopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Retinopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Retinopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Retinopathy drugs and therapies
https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Diabetic Retinopathy Pipeline Market Drivers
• High healthcare Expenditure, increase in patient awareness about diabetes, presence of well-established healthcare infrastructure and favorable reimbursement framework are some of the important factors that are fueling the Diabetic Retinopathy Market.

Diabetic Retinopathy Pipeline Market Barriers
• However, poor access to care, out-of-pocket expenses, insufficient patient knowledge or awareness of Diabetic Retinopathy and other factors are creating obstacles in the Diabetic Retinopathy Market growth.

Scope of Diabetic Retinopathy Pipeline Drug Insight
• Coverage: Global
• Key Diabetic Retinopathy Companies: , and others
• Key Diabetic Retinopathy Therapies: , and others
• Diabetic Retinopathy Therapeutic Assessment: Diabetic Retinopathy current marketed and Diabetic Retinopathy emerging therapies
• Diabetic Retinopathy Market Dynamics: Diabetic Retinopathy market drivers and Diabetic Retinopathy market barriers

Request for Sample PDF Report for Diabetic Retinopathy Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Diabetic Retinopathy Report Introduction
2. Diabetic Retinopathy Executive Summary
3. Diabetic Retinopathy Overview
4. Diabetic Retinopathy- Analytical Perspective In-depth Commercial Assessment
5. Diabetic Retinopathy Pipeline Therapeutics
6. Diabetic Retinopathy Late Stage Products (Phase II/III)
7. Diabetic Retinopathy Mid Stage Products (Phase II)
8. Diabetic Retinopathy Early Stage Products (Phase I)
9. Diabetic Retinopathy Preclinical Stage Products
10. Diabetic Retinopathy Therapeutics Assessment
11. Diabetic Retinopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Diabetic Retinopathy Key Companies
14. Diabetic Retinopathy Key Products
15. Diabetic Retinopathy Unmet Needs
16 . Diabetic Retinopathy Market Drivers and Barriers
17. Diabetic Retinopathy Future Perspectives and Conclusion
18. Diabetic Retinopathy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Diabetic Retinopathy Epidemiology https://www.delveinsight.com/report-store/diabetic-retinopathy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Diabetic Retinopathy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Retinopathy Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer here

News-ID: 3504565 • Views:

More Releases from DelveInsight Business Research

Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epidemiology, Therapies, Companies by DelveInsight | Pfizer, AstraZeneca, Sermonix Pharmaceuticals, Novartis
Breast Cancer Biomarker Market Forecast 2032: FDA, EMA and PDMA Approvals, Epide …
(Albany, USA) DelveInsight's "Breast Cancer Biomarker Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Breast Cancer Biomarker, historical and forecasted epidemiology as well as the Breast Cancer Biomarker market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Breast Cancer Biomarker market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Murine Double Minute 2 (MDM2) Inhibitor Pipeline Analysis 2024: FDA Approvals, C …
(Albany, USA) As per DelveInsight's assessment, globally, Murine Double Minute 2 (MDM2) Inhibitor pipeline constitutes key companies continuously working towards developing Murine Double Minute 2 (MDM2) Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Murine Double Minute 2 (MDM2) Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Murine
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Interstitial Lung Disease Clinical Trials Analysis 2024: FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, Interstitial Lung Disease pipeline constitutes 120+ key companies continuously working towards developing 120+ Interstitial Lung Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Interstitial Lung Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Interstitial Lung Disease Market. The Interstitial Lung Disease
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and companies by DelveInsight | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Myopia Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechan …
(Albany, USA) As per DelveInsight's assessment, globally, about 8+ key pharma and biotech companies are working on 10+ pipeline drugs in the Myopia therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years. "Myopia Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis

All 5 Releases


More Releases for Diabetic

Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Expanding Diabetic Populace Driven Growth For Diabetic Food Market Globally
Market Overview Diabetic Food items are dietary items that incorporate diminished starch and sugar substance that assistance in controlling the ascent of the blood glucose. Diabetic Food additionally contains low calorie sweeteners, slim down refreshments, and so on. These items are devoured by diabetic individuals and by the general population who are not diabetic as careful step to avoid diabetes. Diabetic nourishment makers are entering into different market fragments by presenting
Global Diabetic Footwear Market Is Driven By Growing Diabetic Patients Worldwide
Global Diabetic Footwear Market Report, published by Variant Market Research, forecast that the global market is expected to reach $9.4 Billion by 2024 from $5.3 Billion in 2016; growing at a CAGR of 7.4% from 2016 to 2024. To browse the complete report, visit at https://www.variantmarketresearch.com/report-categories/consumer-goods/diabetic-footwear-market Diabetic footwears are used to reduce foot amputation and ulceration risk in people suffering from diabetes. It is a lifestyle disease. Foot ulceration and debilitating
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be